The US Food and Drug Administration (FDA) has approved Sage Therapeutics’ Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. Until now, treatment for PPD was only available as an IV injection given by a health care provider in certain health care facilities. “Postpartum depression is a serious and potentially […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!